Ask a hundred people in a nerve pain forum about cannabis oil and you get three kinds of answers. It dulled the burning. It helped me sleep through the night. It did nothing for me. All three show up in roughly the same threads, which is the first thing worth knowing before you spend money. Testimonials tell you what a person felt. They do not tell you what will happen in your body, and neuropathy is one of the least predictable pain types to treat, with or without cannabis.

read more

What the testimonials usually describe

Reading through user reports, the same themes repeat. People with diabetic neuropathy often mention a drop in the electric, pins-and-needles sensation rather than full relief. People with post-surgical or chemotherapy-induced nerve damage talk more about sleep and anxiety than about the pain number itself. A smaller group says the oil made them foggy and they stopped. Very few say it erased the pain completely.

related article

Why nerve pain behaves differently

Nerve pain comes from damaged or misfiring nerves, not from tissue injury. That changes which drugs work. Opioids, which are decent for acute pain, tend to disappoint for neuropathy. The standard first-line options are gabapentinoids, certain antidepressants, and topical lidocaine or capsaicin. Cannabis sits outside that list, and the receptors it acts on (CB1 and CB2) are involved in pain signaling, which is why the idea is plausible in the first place. Plausible is not the same as proven.

read more

THC, CBD, or both

Most testimonials you will read involve THC oil, or a balanced oil with roughly equal THC and CBD. That matters, because the two do different things. THC is the part that binds CB1 receptors and produces the high, the drowsiness, and most of the pain-relief signal in the trials that showed anything. CBD does not get you high and has weaker direct evidence for neuropathic pain, though it may help with anxiety and inflammation. Isolated CBD products sold online are often the ones people report doing nothing, and a 2017 review in the journal Current Pain and Headache Reports noted that the positive trial data leaned heavily on THC-containing preparations.

cannabis for nerve pain dosage

What the trials found

This is where testimonials and research part ways. A 2007 study by Nurmikko and colleagues found that a THC-CBD oromucosal spray reduced neuropathic pain intensity compared with placebo, with a modest effect size. A 2010 trial in CMAJ using nabilone for diabetic neuropathy found no significant benefit over placebo. Later reviews have landed in the same murky middle ground: some patients respond, many do not, and the average improvement across a trial is small. Nobody has identified in advance who the responders will be.

Reading a testimonial without getting fooled

  1. Check whether the person names the product, the THC and CBD percentages, and the dose. Vague praise is marketing, not information.
  2. Ignore anyone who says it replaced their prescription. That is a red flag, not a success story.
  3. Look for a timeline. Nerve pain relief that arrives in ten minutes is probably sedation, not analgesia.
  4. Discount any account that mentions a specific brand three times.

Practical notes if you try it

Start low. Oral cannabis oil takes one to three hours to peak, so re-dosing after thirty minutes because nothing happened is how people end up uncomfortable for hours. Keep a written log of dose, time, and pain level, because memory is unreliable here. Alcohol, benzodiazepines, and opioids compound the sedation. If you drive, know that impairment from oral THC can outlast the feeling of being high.

Before you buy anything

Tell your neurologist or pain clinic. Cannabis can interact with gabapentin, duloxetine, warfarin, and some seizure medications. If you are in a state where it is legal, buy from a licensed dispensary with batch testing for pesticides, mold, and heavy metals, since contaminated oil is a real problem in the unregulated market. And if your neuropathy is getting worse rather than stable, that is a medical conversation, not a product problem.